探索药用大麻的潜在抗炎作用。
Exploring potential anti-inflammatory effects of medicinal cannabis.
机构信息
Department Palliative and Supportive Care, 10th floor, Mater Health Services, Raymond Tce, South Brisbane, Queensland, 4101, Australia.
Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia.
出版信息
Support Care Cancer. 2023 Oct 14;31(12):629. doi: 10.1007/s00520-023-08069-8.
PURPOSE
Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties.
METHOD
Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients.
RESULTS
There was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28.
CONCLUSION
We were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients.
TRIAL REGISTRATION
ANZCTR 26180001220257, registered 20/07/2018.
目的
炎症被认为在恶性疾病中起关键作用，并且可能在癌症相关症状的表达中起重要作用。大麻二酚（CBD）是大麻中的一种生物活性化合物，据报道具有显著的抗炎特性。
方法
在一项 CBD 与安慰剂治疗与晚期癌症相关症状的患者的随机对照试验中，测量了所有入组患者的连续 C 反应蛋白（CRP）水平。在这些患者的亚组中，随时间测量了一组炎症细胞因子。
结果
在 CRP 或细胞因子水平从基线到第 28 天的轨迹上，两组之间没有差异。
结论
我们未能证明 CBD 在癌症患者中有抗炎作用。
试验注册
ANZCTR 26180001220257，于 2018 年 7 月 20 日注册。
Zotero 插件